Medication optimization
Phase 3Small molecule
Medication optimization is one of 25 small molecule programs targeting Addiction. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Cancer Pain
#DrugCompanyPhaseTrials
1Duragesic
CCephalon
Approved
Oxycontin
PProtega
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Marinol
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Suboxone
IIndivior Inc.
Approved
Tylenol
KKenvue Brands
Approved
Spravato
WWim Janssens
Approved
Advil
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Medication optimization. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details